News

PipelineReview.com19h

CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings

BERKELEY HEIGHTS, NJ, USA I August 07, 2025 I CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing ...
PipelineReview.com19h

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs) Extended half-life and local bioactivation support convenient once-daily dosing in ulcer ...
PipelineReview.com19h

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

Topline results from CATT1 Phase 3 trial expected in second half of 2026. HIGH POINT, NC, USA I August 07, 2025 I vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceuti ...
PipelineReview.com19h

Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline

Funding will advance Strand’s pipeline and mission to bring targeted, next-generation mRNA therapies to patients ...
PipelineReview.com19h

REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy

ROCKVILLE, MD, USA I August 7, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) today announced it will initiate a pivotal Phase IIb/III clinical trial for ...
PipelineReview.com19h

ProteinQure Receives Regulatory Clearance to Initiate Phase I Trial for PQ203 in the U.S. and Canada; Granted FDA Fast Track Designation

TORONTO, Canada I August 07, 2025 I ProteinQure, a leader in computational protein drug discovery, today announced it has received regulatory clearance from ...